<DOC>
	<DOCNO>NCT00928876</DOCNO>
	<brief_summary>Obesity characterize continuous low-grade inflammation . This important link obesity insulin resistance . Results investigator ' group vitro vivo research mouse show Interleukin-1 involved process develop insulin resistance . Earlier show interleukin-1 receptor antagonist human subject improve glycemic control . The investigator ' hypothesis due improve insulin sensitivity .</brief_summary>
	<brief_title>Interleukin-1 Receptor Antagonist Insulin Sensitivity</brief_title>
	<detailed_description>The prevalence obesity increase fast . Obesity one common acquire risk factor insulin resistance . As consequence prevalence type 2 diabetes mellitus rise fast well . Interleukin 6 Tumor Necrosis Factor alfa well know pro-inflammatory cytokine link insulin resistance . Results group show interleukin-1 also involved process develop insulin resistance . Earlier research project study effect Interleukin-1 receptor antagonist ( Anakinra ) glycemic control subject type 2 diabetes mellitus . It show glycemic control improve . The author conclude result improve function pancreatic beta cell . These result contrast result vitro en vivo research mouse , show improved insulin sensitivity Interleukin-1 receptor antagonist . A possible explanation find effect insulin sensitivity earlier research project may difficult reliable quantify insulin sensitivity group patient concurrent change glycemic control , extensive co-morbidity medication use , might rather extreme end insulin resistance . Furthermore relatively low dose Anakinra use . Altogether hypothesize effect Interleukin-1 mediate well pancreatic beta-cell function , Interleukin-1 block recombinant Interleukin-1 receptor antagonist also diminish insulin resistance .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>adult subject BMI &gt; 30 kg/m2 3 characteristic metabolic syndrome inability give inform consent age &lt; 18 year know diabetes mellitus fast plasma glucose &gt; 7,0 mmol/l HbA1c &gt; 6,2 % presence medical condition might interfere current study protocol immunodeficiency immunosuppressive treatment antiinflammatory drug ( 100 mg aspirin/day allow ) sign current infection history recurrent infection pregnancy breast feed liver disease renal disease neutropenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>anakinra</keyword>
	<keyword>Diabetes mellitus , type 2</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Interleukin-1beta</keyword>
</DOC>